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Abstract
Background: Liver function tests (LFTs) are ordered in large numbers in primary care, and the Birmingham and
Lambeth Liver Evaluation Testing Strategies (BALLETS) study was set up to assess their usefulness in patients with
no pre-existing or self-evident liver disease. All patients were tested for chronic viral hepatitis thereby providing an
opportunity to compare various strategies for detection of this serious treatable disease.
Methods: This study uses data from the BALLETS cohort to compare various testing strategies for viral hepatitis in
patients who had received an abnormal LFT result. The aim was to inform a strategy for identification of patients
with chronic viral hepatitis. We used a cost-minimisation analysis to define a base case and then calculated the
incremental cost per case detected to inform a strategy that could guide testing for chronic viral hepatitis.
Results: Of the 1,236 study patients with an abnormal LFT, 13 had chronic viral hepatitis (nine hepatitis B and four
hepatitis C). The strategy advocated by the current guidelines (repeating the LFT with a view to testing for specific
disease if it remained abnormal) was less efficient (more expensive per case detected) than a simple policy of
testing all patients for viral hepatitis without repeating LFTs. A more selective strategy of viral testing all patients
for viral hepatitis if they were born in countries where viral hepatitis was prevalent provided high efficiency with
little loss of sensitivity. A notably high alanine aminotransferase (ALT) level (greater than twice the upper limit of
normal) on the initial ALT test had high predictive value, but was insensitive, missing half the cases of viral
infection.
Conclusions: Based on this analysis and on widely accepted clinical principles, a “fast and frugal” heuristic was
produced to guide general practitioners with respect to diagnosing cases of viral hepatitis in asymptomatic
patients with abnormal LFTs. It recommends testing all patients where a clear clinical indication of infection is
present (e.g. evidence of intravenous drug use), followed by testing all patients who originated from countries
where viral hepatitis is prevalent, and finally testing those who have a notably raised ALT level (more than twice
the upper limit of normal). Patients not picked up by this efficient algorithm had a risk of chronic viral hepatitis
that is lower than the general population.
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Liver Function Tests are ordered in large numbers in
primary care
Liver function tests (LFTs) are comprised of a panel of five
to eight analytes that are processed inexpensively in large
batches. LFTs are one of the most commonly performed
“blood tests” in primary care, such that in 2003 the labora-
tory at University Hospital Birmingham received 67,182
requests for LFTs from 83 General Practitioner (GP) prac-
tices, serving a population of 300,000 (Cramb R; Chemical
Pathology Specialist).
Enigmatic responses to abnormal LFTs in primary care settings
An abnormal LFT may signify a serious disease that can be
identified only through further testing. These conditions
include liver diseases, such as primary biliary cirrhosis
(PBC), diseases of other organs such as Paget’s disease of
bone, and multi-organ diseases such as haemochromato-
sis. However, the majority of people with an abnormal
LFT in primary care settings will not have any such pre-
viously undetected disease. They will have either no dis-
ease at all, or will be manifesting the effects of alcohol
abuse or obesity. The doctor is likely to be aware, or at
least suspicious, of these behaviours when ordering LFTs,
but this does not exclude the presence of other diseases
that may aggravate liver damage. There is thus a real ques-
tion about which specific further tests, if any, a GP should
order when an abnormal LFT result is obtained in a
patient with non-specific symptoms, or as a result of rou-
tine testing. In some cases there may be a clear indication
for further tests. For example, if the patient has a family
history of haemochromatosis then their iron saturation
should be measured. In some cases the pattern of LFT
abnormality may suggest a diagnosis - for example, an iso-
lated raised unconjugated bilirubin suggests Gilbert’s dis-
ease, while a high blood level of alkaline phosphatase
(ALP) is indicative of PBC. In most cases however, no
unambiguous clinical indication for follow-on testing
exists. The literature deals mostly with the pattern of
abnormality given a diagnosis, rather than the probability
of the various diagnoses given a pattern of abnormal LFTs.
It is therefore not surprising that guidelines for GPs [1-5]
confronted by an abnormal LFT in patients with non-spe-
cific symptoms or detected fortuitously are inconsistent,
or that the way GPs respond has been found to be eclectic
[6]. A point on which guidelines do agree is that the LFT
panel should be repeated following an abnormal result.
Criteria for selection of a topic for decision analysis
If there is any particular previously unrecognised disease
that a patient would wish to have excluded by further
testing, then it will have the following features:
1. it is a serious disease;
2. it is treatable in the prodromal phase;
3. failure to identify the condition can lead to per-
manent damage;
4. it can be diagnosed with a high specificity by a
familiar and inexpensive test;
5. it is among the more prevalent of the serious
diseases;
6. it is not a condition such as alcohol misuse or
obesity, which can be diagnosed from history and
examination.
Viral hepatitis
We discern that chronic viral hepatitis is the prime can-
didate based on the above criteria. It is a massive pro-
blem worldwide [7-9] and Table 1 shows that it is the
most common of the specific liver diseases in the UK
population after alcohol damage. Moreover, chronic
viral hepatitis can be reliably confirmed or excluded by
means of a relatively inexpensive blood test [10,11]. The
disease has a prodromal period lasting many decades
and is eminently treatable if caught early, thereby avert-
ing cirrhosis and liver cancer [12,13].
The purpose of the decision analysis described here is
to inform the selection of an efficient strategy for the
diagnosis of chronic viral hepatitis. Such a strategy
should optimise the trade-off between detection rate
and cost.
Methods
The BALLETS study
The objective of the BALLETS study was to correlate the
pattern of abnormal LFTs in primary care with the ‘final’
diagnosis. This was accomplished by fully investigating a
cohort of patients with abnormal LFTs and no known
liver disease by means of a panel of tests for the specific
viral, auto-immune and genetic diseases shown in Table
1. This comprehensive investigation by means of the
standard “liver panel” acts like a concertina, bringing for-
ward the diagnosis of conditions, such as viral hepatitis
and PBC, that would take years or decades to manifest if
followed-up in the usual way. The BALLETS study was
funded by the UK National Institute for Health Research
through its Health Technology Assessment (HTA) pro-
gramme. The full protocol is available online [14].
Patients were recruited from eight Birmingham and
three Lambeth practices from November 2005 to Novem-
ber 2008. The cohort was formed from patients with at
least one abnormal analyte (from a panel of eight - alanine
aminotransferase (ALT), aspartate aminotransferase
(AST), ALP, bilirubin, gamma-glutamyltransferase (GGT),
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known liver disease. The biochemical measurements were
carried out in three Clinical Pathology Accreditation UK
(CPA UK) laboratories (conforming to International Qual-
ity Control Standards) in Birmingham and Lambeth.
Laboratory specific ranges (incorporating age and sex
adjustments for ALT, ALP and GGT) were used to define
abnormality. Eligible patients from the participating GP
practices were invited to attend special study clinics where
the following information was obtained:
· Clinical data, including: country of birth, alcohol
history, Body Mass Index (BMI), drug and medicine
use, and reason for LFT testing.
· A repeat LFT.
· Blood tests for specific diseases (Table 1). Investiga-
tions for viral hepatitis tests included hepatitis B
viral markers (HBV Surface Ag) and hepatitis C
virus antibody (HCV Ab) [10,11].
· Ultrasound of upper abdomen.
Patients were followed up for two years, at which
point LFTs were repeated along with a further ultra-
sound of the upper abdomen (results of the follow-on
study will be reported at a later date).
Testing strategies
A simple decision tree was constructed in Microsoft
Excel (Microsoft Corp., Redmond Washington) to
enable costs per case detected to be calculated for seven
strategies [15]. The strategies were developed in consul-
tation with a GP and hepatologist (P. Gill and J. Neuber-
ger respectively) who were aware of the relevant
literature and guidelines.
The root decision (or starting point) of the tree is the
discovery of an abnormal LFT in primary care where the
patient does not have known or self-evident liver disease.
From the root node we identified seven decisions that
may be considered by a GP under such a scenario:
■ Strategy A: repeat the LFT panel and then per-
form a specific test for viral hepatitis if an abnormal-
ity is still present on re-testing. This could be
considered the intuitive response by a GP on receiv-
ing an abnormal LFT in a patient without the indic-
tors of a specific disease, and is the strategy
recommended in the literature [1-5].
■ Strategy B: perform a viral test in all patients with
an abnormal ALT. The rationale for this strategy is
that ALT is the most specific indicator of viral hepa-
titis [4], and has been recommended as the testing
criterion by other authors [16-18].
■ Strategy C: select ALT as the trigger for viral test-
ing, but nominate a higher threshold at twice the
upper limit of normal, as recommended by Jamali
[19]. This is also the threshold for instigating viral
therapy for HBV in certain treatment guidelines
[20-22].
Table 1 Viral, genetic, and autoimmune diseases of the liver (tested for by a “liver panel”), their prevalence in the
British population and diagnostic algorithms*
Disease Prevalence amongst adult
population (%)
Blood tests done on all members of
the cohort (to diagnose or screen for
the disease)
Diagnostic algorithm
Chronic viral
hepatitis C
0.42 [46] Hepatitis C virus antibody (HCV Ab) Viral marker positive.
Chronic viral
hepatitis B
0.3 [47] Hepatitis B viral markers (HBV Surface Ag) Viral marker positive.
Metal storage
disease: Iron
0.25 (prevalence of phenotype;
homozygous plus complex
heterozygous) [48]
Iron saturation Genotype if iron saturation >50%.
Primary
biliary
cirrhosis
(PBC)
0.024 [49] Antimitochondrial Ab Raised antibodies and raised ALP level.
Autoimmune
hepatitis
0.001 [50] Smooth Muscle Ab Raised antibodies and raised ALT, AST or globulin
exceeding twice the upper limit of normal.
Confirmed by hepatologist.
Metal storage
disease:
Copper
<0.025 [51] Caeruloplasmin Low levels of caeruloplasmin.
Alpha-1
antitrypsin
deficiency
<0.025 [52] Alpha-1 antitrypsin Low Alpha-1antitrypsin levels followed by phenotype
testing.
*Method by which the diagnosis was made.
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patients who originate from a country with an inter-
mediate or high prevalence of viral hepatitis according
to World Health Organisation (WHO) criteria [23-25].
Screening has been shown to be cost-effective for peo-
p l ew h ow e r eb o r ni np r e v a l e n tc o u n t r i e sa n di ti s
likely that testing would be more cost-effective still in
a population with abnormal LFTs [21,26].
■ Strategy E: combine the two previous strategies by
testing those who have an ALT exceeding twice the
upper limit of normal and who also originate from a
prevalent country.
■ Strategy F: test all patients from prevalent coun-
tries as well as those with an ALT exceeding twice
the upper-limit of normal.
■ Strategy G: test all patients for viral hepatitis irre-
spective of the type or extent of abnormal LFT
results.
There is also an option to take no action with respect
to viral hepatitis, and while this may be a sound decision
in some cases, for example when a LFT is ordered in
the hope that a positive result will prompt a reduction
in alcohol intake, this was not considered here.
In this study the hepatitis status for all patients was
known. Moreover most had an ALT test result and the
results of a repeat LFT panel. Thus it was possible to
evaluate the performance of each of the above strategies.
Populating the decision tree with probabilities/statistical
model
All 1,236 patients were used in the evaluation of strategy
G, but for all other strategies the effective sample size
was reduced because of missing data in some of the
patient records. Estimates of the proportion of patients
undergoing viral tests, and the proportion of actual cases
detected (sensitivity) were obtained using the sample of
patients available for evaluating each strategy. The posi-
tive predictive value of a strategy was defined as the pro-
portion of hepatitis cases among those selected for viral
testing. Confidence limits for this quantity were calcu-
lated using Wilson’s method for Binomial data [27].
Estimation of costs
The direct costs incurred at the time of the test were the
laboratory costs of the liver function and viral hepatitis
tests (personal correspondence with Pathology Lab Man-
ager); the GP costs for scheduling each test; and follow-
ing up on results. Administrative costs were estimated by
estimating the time implications for a secretary to add
patients to appointment slots and a receptionist to check
the patient in for an appointment (personal correspon-
dence with MidReC: West Midlands Research Consor-
tium. Figures correct as of February 2009). The costs are
presented in pounds sterling (£) (and were correct for the
year 2009). Non-health service costs (patient travel cost
and lost earnings) were not measured, but are considered
in the discussion.
Analysis
The number of cases detected per 100 patients was esti-
mated as the sensitivity of the strategy (cases detected
divided by cases present) multiplied by the prevalence
(per 100 patients) of viral hepatitis in the whole sample
of 1,236 patients. For each strategy the cost per case
detected was then computed as the ratio of the cost per
patient to the number of cases detected per patient. The
strategy which minimised this quantity was taken as the
base case. For each alternative strategy the incremental
cost-effectiveness ratio (ICER) was computed, defined as
the incremental cost per additional case detected com-
pared to the base case. The analysis is deterministic and
does not consider the impact of sampling variability. The
results of these analyses were compared with published
results of cost-effectiveness analysis of screening for
chronic viral hepatitis, bearing in mind likely differences
between a screening and a diagnostic population. We
used this analysis to develop a “fast and frugal” heuristic
[28] which we offer to readers for their consideration.
Results
Patients
One thousand, three hundred and forty-four patients
consented to the study. Fifty-four were excluded because
they did not match the entry criteria in the protocol,
along with a further 54 where data on at least one viral
hepatitis test was missing (Figure 1). This left 1,236
patients for this study. One hundred and five of these
patients were from Lambeth and 1,131 were from Bir-
mingham. The median interval between index and repeat
testing was 31 days (inter-quartile range 19-52 days).
Patients who agreed to participate
1,344
Included in BALLETS
1,290
Included in this study
1,236
Birmingham 1,131 Lambeth 105
Excluded: Index test not abnormal 46
Follow-up test missing 8
Excluded: Viral test missing 54
Figure 1 Flow diagram of exclusions and inclusions in the
study.
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Thirteen of the 1,236 patients where the test result was
available had chronic viral hepatitis - nine cases of hepati-
tis B and four cases of hepatitis C. This gives an estimate
of 1.1% (95% CI: 0.6%-1.8%) for the prevalence rate in a
primary care population with abnormal LFTs; only slightly
more than the baseline prevalence in the general popula-
tion (0.7%). The demographic breakdown of patients with
and without viral hepatitis is shown in Table 2.
The breakdown LFT results in the infected cases is
given in Table 3. In 10 of these 13 cases, more than one
analyte was abnormal. In eight cases the ALT was
abnormal and was notably raised in six of those (above
twice the upper limit of normal). In one case (perhaps
detected by serendipity) only protein levels were abnor-
mal and all the enzyme tests (ALT, AST, GGT and
ALP) were normal. Eleven of the 13 patients with
chronic viral hepatitis had an abnormality on the repeat
LFT. There were two other cases where there were
missing data among the repeat LFT panels. Of the 1,113
patients with no viral hepatitis who underwent a com-
plete LFT panel, 169 (15%) reverted to normal.
The country of origin was recorded in 1,208 of the
1,236 study cases, and of these, 170 people were born in
a country with an intermediate or high prevalence of
viral hepatitis (based on WHO definitions of prevalence
[23-25]) and 1,038 were from low-risk countries. The
h i g h - r i s kg r o u pc o n t a i n e d1 1o ft h e1 3c a s e s( 8 5 % )o f
viral hepatitis. None of the 13 cases admitted to use of
intravenous drugs at any time.
As expected from the literature, ALT or AST levels
when abnormal tended to be more extreme for cases with
viral hepatitis than for cases that did not have this disease
(Table 4).
Diagnostic performance
The sensitivity and positive predictive value of each
detection strategy are given in Table 5. It can be seen
that the recommended strategy (A), of repeating the
LFT and then doing a viral test if an abnormality per-
sists, is highly sensitive. However, the predictive value is
low (1.15%). Strategy D, simply carrying out a viral test
if the patient originates from a high or intermediate risk
country, detects 85% of cases and has a much higher
predictive value of 6.47% than the strategy of repeating
the LFT test. The strategy of ordering an LFT if the
ALT is raised (B), is neither particularly sensitive (67%),
nor does it have a high predictive value (1.91%). The
more selective strategy of testing if the index ALT was
over twice the upper limit of normal (C) has a higher
Table 2 Demographic features of patients with and without viral hepatitis
Total Viral Hepatitis Not Viral Hepatitis
N 1236 13 1223
Age
Mean (SD) 57.7 (15.2) 54.0 (15.9) 57.7 (15.2)
Sex
Male 693 (56.1%) 9 (69.2%) 684 (55.9%)
Female 543 (43.9%) 4 (30.8%) 539 (44.1%)
Ethnic group
White 1023 (82.8%) 3 (23.1%) 1020 (83.4%)
Asian 88 (7.1%) 5 (38.5%) 83 (6.8%)
Black 53 (4.3%) 3 (23.1%) 50 (4.1%)
Other 38 (3.1%) 2 (15.4%) 36 (2.9%)
Missing 34 (2.8%) - 34 (2.8%)
Reason
Abdominal signs/symptoms 69 (5.6%) 1 (7.7%) 68 (5.6%)
Non-abdominal signs/symptoms 302 (24.4%) 6 (46.2%) 296 (24.2%)
Diagnosis - Alcohol abuse 17 (1.4%) 0 (0.0%) 17 (1.4%)
Review - CVD 50 (4.0%) 0 (0.0%) 50 (4.1%)
Review - Cholesterol 53 (4.3%) 0 (0.0%) 53 (4.3%)
Review - Hypertension 147 (11.9%) 2 (15.4%) 145 (11.9%)
Review - Diabetes 216 (17.5%) 2 (15.4%) 214 (17.5%)
Review - Medication 92 (7.5%) 0 (0.0%) 92 (7.4%)
Medical - Review other 290 (23.5%) 2 (15.4%) 288 (23.5%)
CVD: Cardiovascular Disease.
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of C and D are combined in the hybrid strategy F which
achieves high sensitivity (92%) and worthwhile predictive
value (5.12%).
Costs and Cost Minimisation Analysis
The cost of the laboratory tests and the practice costs
are given in Table 6. The average cost per case detected
and the incremental costs of detecting each additional
case are shown in Table 7. Strategy E (viral test if
patient born in an intermediate/high-risk country and
ALT is greater than twice the upper limit of normal)
provides the lowest cost per case detected. This strategy
was therefore designated as the base case for the calcu-
lation of the ICERs. Strategy A, the intuitive and widely
advocated practice of repeating LFTs, turns out to be
the most expensive per case detected. It is dominated
by strategy G, where all patients have a viral test. Simi-
larly strategy B (viral test if the index ALT is abnormal)
is dominated by strategy D (perform viral test if patient
w a sb o r ni na ni n t e r m e d i a t eo rh i g hr i s kc o u n t r y ) .
Strategy C (viral test if the ALT is greater than two
times the upper limit of normal) can be eliminated by
an extended dominance principle. If strategy C is pre-
ferred to E, this can only be because the extra cases
detected by C are deemed worth the extra cost. How-
ever, strategy D finds yet more cases than C at lower
incremental cost. Therefore either E or D are preferable
to C. The cost-effectiveness of the remaining admissible
strategies can be visualised from Figure 2. The dotted
lines join strategies that cannot be eliminated by domi-
nance principles. The absence of any explicit penalty for
missing cases of viral hepatitis in this analysis implies
that the costs of E, D and F are under-estimated with
respect to G. However, F must be regarded as highly
competitive with G - it picks up almost as many cases
and has very high efficiency in terms of cost per case
detected.
Table 3 Results of initial LFT for viral hepatitis cases using laboratory-specific criteria for abnormality
Case
No.
ALT AST Bilirubin ALP GGT Albumin Globulin Total
Protein
Repeat LFT Country of Origin (prevalence of
viral hepatitis)
HBV 1 High* High Normal Normal High Normal Normal High Abnormal Kenya (High)
2 Normal Normal High Normal Normal High Low Normal Abnormal UK (Low)
3 High Normal Normal Normal High Normal Normal Normal Abnormal Pakistan (High)
4 High* High High Normal High Normal Normal High Abnormal India (High)
5 High* High Normal Normal Normal Normal Normal Normal Abnormal Malaysia (High)
6 High* No
result
No
result
No
result
Normal Normal Normal Normal Abnormal UK (Low)
7 Normal Normal Normal Normal Normal Normal High High Abnormal Kenya (High)
8N o
result
High Normal High No
result
Normal No result No result Abnormal Iraq (High)
9 Normal No
result
High Normal No
result
Normal No result No result Incomplete** Malta (High)
HCV 1 High Normal Normal Normal High Normal Normal Normal Incomplete Pakistan (High)
2 High* High Normal Normal Normal Normal Normal High Abnormal Hong Kong (High)
3 Normal No
result
Normal Normal High Normal No result No result Abnormal Jamaica (High)
4 High* High Normal Normal Normal Normal Normal Normal Abnormal Somalia (High)
* Denotes where ALT values were greater than twice the upper limit of normal.
** Repeat test available for AST and GGT only, both of which were normal.
ALT: Alanine aminotransferase;
AST: Aspartate aminotransferase;
ALP: Alkaline phosphatase;
GGT: Gamma-glutamyltransferase;
HBV: Hepatitis B;
HCV: Hepatitis C.
Table 4 Comparison of ALT and AST results in HBV or
HCV cases versus non-hepatitis cases
Upper limit HBV or HCV Non-hepatitis
Analyte N Mean Median N Mean Median
ALT 41 8 98.0 89.5 426 65.4 56.0
AST 43 6 94.5 69.5 254 64.5 53.5
Only cases where analyte is abnormal are included in this table.
ALT: Alanine aminotransferase;
AST: Aspartate aminotransferase;
HBV: Hepatitis B;
HCV: Hepatitis C.
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Summary of main findings
The BALLETS study is the first GP based study where the
entire cohort was comprehensively tested for additional
diseases (such as viral hepatitis) after an abnormal LFT,
using the full analyte panel and normal reference ranges.
We have shown that an abnormal LFT alone does not
select out a population where the prevalence rate
approaches a threshold which would justify viral screening.
We have assessed the validity of the various strategies a
GP could adopt, at least as far as viral hepatitis is con-
cerned, when faced with an abnormal LFT of uncertain
provenance. The intuitive response for a GP in such a
situation would be to repeat the LFT, an approach advo-
cated by current literature. This study shows that this may
not be the optimal policy. This strategy is the most expen-
sive, even more so than viral testing all patients, as the
costs incurred include repeating the LFT as well as viral
testing the majority. The study also shows that if ALT is
notably raised (greater than twice the upper limit of nor-
mal), then the probability of chronic viral hepatitis is high
(nearly 8%), but sensitivity is low. The strategy of testing
all people from prevalent countries is the second most effi-
cient, in terms of cost per case detected, and detects
almost twice as many cases as the most efficient strategy -
testing for viral infection when two conditions (birth in a
prevalent country and an ALT greater than twice the
upper limit of normal) are satisfied. The relative financial
disadvantages of the strategy of repeating the LFT would
be even greater if patient costs were included, as the extra
visit would have to be factored in.
Previous literature on LFTs and liver diseases
We conducted a literature review using the search strat-
egy shown in Table 8, with the aim of retrieving papers
that studied a cohort of patients with abnormal LFT
results to provide evidence on the probability of various
liver diseases (including chronic viral hepatitis) given
abnormal test results. Any such studies would enable
the precision of our observations to be strengthened.
The search strategy returned 1,448 papers, including a
previous review by Dufour et al. (2000) [29].
Only eight studies matched our requirement of follow-
ing up patients with an abnormal LFT result. Two addi-
tional articles were selected from the references of
relevant studies. As a result, to the best of our knowl-
e d g e ,t h e r ea r eo n l yt e ns t u d i e sw h e r eac o h o r to f
asymptomatic patients with abnormal LFTs were
Table 5 Yield, sensitivity and Positive Predictive Values (PPV) of different detection strategies
Strategy for viral testing No. of
patients*
Hepatitis
cases*
Viral
tests
Cases
detected
Sensitivity
(%)
PPV (%) 95%
Confidence
Limits
A. If repeat LFT panel is abnormal 1124 11 955 11 100 1.15 (0.64-2.05)
B. If ALT abnormal on primary test 1064 12 418 8 67 1.91 (0.97-3.73)
C. If ALT > 2 upper limit of normal on primary test 1064 12 77 6 50 7.79 (3.62-15.98)
D. If patient born in a country of intermediate to high viral hepatitis
prevalence.
1208 13 170 11 85 6.47 (3.65-11.21)
E. If patient born in a country of intermediate to high viral hepatitis
prevalence and ALT > 2 upper limit of normal on primary test.
1041 12 16 5 42 31.25 (14.16-
55.60)
F. If patient born in a country of intermediate to high viral hepatitis
prevalence, or ALT > 2 upper limit of normal on primary test.
1041 12 215 11 92 5.12 (2.88-8.93)
G. Test all cases 1236 13 1236 13 100 1.05 (0.62-1.79)
Testing patients for viral infection on the basis of country of origin is more sensitive and has much higher positive predictive value.
* The sample of patients available to evaluate each strategy varies because of patterns of missing data, as follows:
A requires a complete panel of follow-up LFTs, the missing data in the two cases that were not abnormal might have led to an exagerated estimate of
sensitivity;
B and C both require an initial ALT test;
D requires information on country of birth;
E and F require an initial ALT together with country of birth.
All evaluations require results of viral tests for both Hepatitis B and Hepatitis C.
ALT: Alanine aminotransferase;
LFT: Liver function test.
Table 6 Cost estimates for resources used
Cost categories Resources
GP consultation cost to check LFT results £12.86 *
Receptionist to check patient in for appointment (2 mins) £0.91*
Secretary time (1 min) £0.33*
Phlebotomist time (5 mins) £1.00*
Sample analysis: LFT £2.69**
Sample analysis: Hepatitis B surface Ag and Hepatitis C £25.42**
* Source: Midlands General Practice Research Consortium (MidReC, Feb 2009).
** Source: University Hospital Birmingham, NHS Foundation trust (2009).
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Page 7 of 13followed up (Table 9). However, one article was written
in Korean (only the abstract was translated), so was
excluded from our analysis.
Two of the remaining nine English language papers
described record linkage studies. One such study was
based on the Korean insurance database that was linked
with death certificates [30]. This study reported that
increased ALT, even within the upper end of the nor-
mal range, was associated with eventual death from
liver disease. A study carried out in Scotland linked
general practice and hospital databases [31,32]. How-
ever, this was a retrospective study so a full liver screen
was not conducted and follow-up was for a median of
four years only, whereas many diseases, including
chronic viral hepatitis, have much longer prodromal
periods [33].
The other seven studies were prospective cohort stu-
dies, based on testing asymptomatic members of the
general population. The famous Dionysos study based
on three analytes from the LFT analyte panel [34] is
included among these. In this study an impressive 6,917
citizens from two communities in northern Italy were
screened. Although they tested all those who had an
abnormal LFT (n = 1473) for viral hepatitis, for which
they found a prevalence rate of 2.4%, they did not
describe the pattern of LFT results in infected patients.
Another Italian study by Pendino and colleagues (2005)
screened 1,645 inhabitants from a town in southern
Italy, with both a LFT (ALT, AST and GGT) and viral
screen [35]. The prevalence of viral hepatitis is much
higher in this region because of a significant immigrant
population, and they performed a more extensive analy-
sis on the impact of viral hepatitis on LFTs. Of the 319
(19.4%) individuals who received an abnormal LFT,
nearly 18% were infected with viral hepatitis. However,
the LFT missed 34 (40%) of the 92 cases of viral hepati-
tis present in the community. Perhaps the most compre-
hensive prospective analysis looking at the effect of viral
hepatitis on the individual analytes was carried out on a
population of Japanese office workers [16]. The study
used data from compulsory health checks, which
included an ALT, AST and GGT panel along with cer-
tain additional tests, such as a viral screen, that were
added for study purposes. They found that ALT was the
most sensitive of the three analytes used, detecting
Table 7 Economic analysis
Strategy Cost per 100
patients (£)*
Cases detected
per 100 patients
Cost per case
detected (£)
Incremental cost per 100
patients (with base = E)
Incremental cases detected per
100 patients (base = E)
ICER
A 5222 1.05 4965 5159 0.61 Dominated**
B 1592 0.70 2270 1530 0.26 Dominated
†
C 293 0.53 558 231 0.09 (2635)
‡
D 570 0.89 641 508 0.45 1124
E (base)
§ 62 0.44 142 0 0.00 Base
F 837 0.96 868 775 0.53 1473
G 4052 1.05 3853 3990 0.61 6503
* Cost of Viral test = £40.52; Cost of LFT Panel = £17.79.
** Dominated by G.
† Dominated by D and F.
‡ Strategy C is eliminated by extended dominance.
§ Patient born in a country of intermediate to high viral hepatitis prevalence and ALT greater than twice upper limit of normal on primary test is the least
expensive strategy and was considered as base case.
ICER: Incremental cost-effectiveness ratio.
LFT: Liver function test.
Figure 2 Cost per detected case for seven testing strategies.
The number of detected cases per patient is estimated as
(Sensitivity of strategy) × 1.05% where the latter figure is the viral
hepatitis prevalence observed in the complete sample of 1,236
patients. The number used differs slightly from the actual number
of cases detected per patient in table 5 because of variation in the
prevalence of the condition across the samples in which each
strategy was tested. The current approach achieves a more
consistent comparison of strategies within our data-set; for example,
it ensures that the estimate of detected cases per patient for a
strategy with 100% sensitivity will always be at least as great as that
of any other strategy.
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Page 8 of 13Table 8 Search strategy for studies looking prospectively at patients who have received an abnormal LFT*
Liver Function Test Search Strings (limited using the subheadings; blood, analysis and
metabolism)
Hepatitis Search Strings
Liver Function Test Liver Diseases (diagnosis)
Transaminases Liver Diseases (epidemiology)
Alanine Aminotransferases Liver Diseases (enzymology)
Aspartate Aminotransferases Liver Diseases (virology)
Alkaline Phosphatase Liver Diseases
Gamma-Glutamyltransferases
With Limits added (Humans and Pub date post 1980) With Limits added (Humans and Pub date post
1980)
Papers returned = 35070 Papers returned = 8526
When strategies combined using term AND = 1448 papers whose abstracts were read
*Based on Medline and limited to human studies after 1980.
Table 9 Studies that have followed up patients from the general population after abnormal LFT
Author and
Country
Date Type of Study and
population studied
Analytes Used Patients
enrolled
Patients
with
abnormal
LFTs (%)
Prevalence of
viral hepatitis in
patients with
abnormal LFTs
Notes
McLernon DJ
et al. [31]
Scotland
2009 Record Linkage;
laboratory database of
GP tests, hospital
admissions and death
certificates.
Bilirubin, Albumin, ALP, GGT,
ALT, AST (transaminases
sometimes combined). GP
selected
95,977 20,827
(21.7%)
2.2% Median follow up of
3.7 years. Risk of
under ascertainment.
Pendino GM
et al. [35] Italy
2005 Prospective Cohort Study;
general population.
AST, ALT, GGT. 1,645 319
(19.4%)
17.9% High baseline rate of
viral hepatitis; 5.6%.
Kim HC et al.
[30] Korea
2004 Record Linkage:
insurance data and death
certificates.
AST, ALT. 142,055 11,193
(7.9%)
N/A Outcome was liver
disease mortality.
Yano E et al.
[16] Japan
2001 Prospective Cohort Study;
“healthy” office workers.
AST, ALT, GGT. 1,973 358
(18.1%)
2.7% Assumed that all liver
cancer and cirrhosis
was a result of viral
hepatitis.
Daniel S et al.
[36] USA
1999 Prospective Cohort Study;
primary care population.
ALT, AST raised 50% above
normal on at least two
occasions across a six month
period.
1,124 1,124
(100%)
N/A Marker was negative
patients only, so
infected patients
excluded from
analysis.
Mathiesen UL
et al. [37]
Sweden
1999 Prospective Cohort Study;
primary care population.
AST, ALT raised for at least 6
months. (ALP had to be
normal).
150 150 (100%) 15.3%
Whitehead
MW et al. [39]
UK
1999 Prospective Cohort Study;
primary care population.
AST markedly raised (10
times (>400 U/l) above the
upper limit of normal.)
137 137 (100%) 2.2%
Bellentani S
et al. [34] Italy
1994 Prospective Cohort;
general population.
AST, ALT, GGT. 6,917 1,473
(21.3%)
2.4%
Hultcrantz R et
al. [38]
Scandinavia
1986 Prospective Cohort Study;
primary care population.
AST, ALT moderately raised
for at least 6 months.(ALP
had to be below twice the
upper limit of normal).
149 149 (100%) 2.7%
We also identified a relevant study by Kim and colleagues. This study prospectively followed a group of “healthy” Korean factory workers taking measurements
of ALT, AST and GGT on at least two separate occasions. The full article was in Korean so we only had access to the abstract [53].
ALT: Alanine aminotransferase;
AST: Aspartate aminotransferase;
ALP: Alkaline phosphatase;
GGT: Gamma-glutamyltransferase;
HBV: Hepatitis B;
HCV: Hepatitis C;
LFT: Liver function test.
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Page 9 of 13nearly half the cases of viral hepatitis, whilst being
abnormal in 14% of the cohort (278 abnormal results in
1,973 participants). The remaining four prospectively
designed studies were carried out in general practices
and were therefore closer in population terms to the
BALLETS cohort. However, three of these were
restricted to patients with persistently abnormal LFTs
over a six month period [36-38] and one of these did
not include a test for viral hepatitis. The final prospec-
tive study by Whitehead (1999) was small and based on
only one analyte [39].
After this review of the literature we concluded that
there has been no published study that fully investigated
a cohort of patients in primary care with an abnormal
LFT result (from the full LFT analyte panel).
Strengths and limitations of the study
The main strength lies in the unique nature of the BAL-
LETS cohort, being the only prospective study that has
looked at the consequences of an abnormal LFT from a
full analyte panel in primary care. The main limitation
of our study relates to the rather small number of cases
of chronic viral hepatitis (n = 13) and hence wide confi-
dence limits on the results. That said the results are
plausible, in the sense that they are consistent with the
pathophysiology of hepatitis and in line with what was
found in non-practice settings (see literature review
above). They are available for meta-analysis with poten-
tial future studies.
We deliberately selected multi-cultural inner city
populations in order to provide a sizable sub-group of
people from countries where chronic viral hepatitis is
common, as a result of infection during infancy (hepati-
tis B),[40] and iatrogenic infection (hepatitis C).
Our study considers only one disease type, chronic
viral hepatitis, while GP decision making must take into
account other diseases, such as haemochromatosis, as
well as other behavioural and social motivations for test-
ing [41,42]. That said, our conclusion that repeating the
LFT “offers more than it delivers,” may well apply to
diseases such as PBC and haemochromatosis.
Lastly we have presented an analysis for cost minimisa-
tion and incremental cost per case detected. This is not a
full cost-effectiveness or decision analysis. Donnan et al.
did attempt a decision analysis [32]. However this deci-
sion analysis was intended to find the most cost-effective
strategy in the short term and used a limited time hori-
zon of one year. LFTs are often ordered to prevent poor
outcome in the long term, with many serious liver dis-
eases, viral hepatitis included, manifesting over decades.
Anxiety resulting from a false positive result was included
in the model while long term health gains as a result of
successful case finding and treatment were not captured.
Neither our decision analysis, nor that in Donnan’s
HTA report [32], considered cost-effectiveness. We
tackle this limitation by considering our results in the
context of published cost-effectiveness analyses for
screening for viral hepatitis (i.e. studies that found
screening was cost-effective in populations with high
prevalence rates e.g. migrants) and attempt to produce a
“fast and frugal heuristic” [28] to guide practice.
Implications for practice: a fast & frugal heuristic
The intuitively appealing practice of repeating abnormal
LFTs (strategy A) gets little support from our analysis.
It is the most expensive option, both in absolute terms
and in terms of cost per case detected, compared to all
five alternative strategies (Table 7) - including that of
simply testing everyone for viral infection.
The most important question a doctor can ask a
patient with abnormal LFTs is their country of origin.
This holds good whether the person settles in an area of
high or low ethnic mix, since infections are acquired in
infancy (hepatitis B), or as a result of sub-standard med-
ical practices, such as needle sharing (hepatitis C). Once
infected, people “take their risk with them” - less people
will need to be tested in a low ethnic mix area, but
those from prevalent countries still need testing. The
strategy of testing people from prevalent countries
promises good value for money. In this study, 11 of the
13 cases originated in medium or high risk countries.
Thus the prevalence of chronic hepatitis viral infection
(positive predictive value) among people with an abnor-
m a lL F Tw h ow e r eb o r ni nap r e v a l e n tc o u n t r yw a s
6.5% (11/170, 95% CI: 3.7%-11.2%, see table 5), while
t h ep r e v a l e n c ea m o n gt h eh o m eb o r np o p u l a t i o n( o fa l l
ethnic groups) was less than 0.2% (2/1038, CI: 0.05%-
0.7%). Our findings support viral testing only in the for-
mer group, consistent with the threshold prevalence for
both HBV and HCV, of approximately 3% at which
population screening becomes cost-effective [21,43,44].
Four of the strategies, C, D, E and F, entail viral testing
in a population where the rate of hepatitis exceeds the
3% threshold for which testing has proven cost-effective
in screening programs (Table 5). The cost-effective
threshold is probably a little lower in a diagnostic popula-
tion than in a screening population (costs of inviting peo-
ple to attend are lower and cases detected might be a
slightly higher risk) but no other strategy yields a popula-
tion with a hepatitis rate exceeding even 2%.
Strategy D (test immigrants from prevalent coun-
tries) has a better (lower) incremental cost-effective
ratio than C and detects twice as many cases as E.
However, the strategy F, testing immigrants from pre-
valent countries or any people with a very high ALT, is
our preferred strategy, being both sensitive and
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Page 10 of 13efficient. We therefore recommend the “fast and fru-
gal” heuristic described in Figure 3. This combines
strategy F with normal judgement of clinical indica-
tions. For example a patient who is an intravenous
drug user, or who has recently returned from a trip
abroad where they had an attack of hepatitis, would be
tested notwithstanding the result of the LFTs. Other-
wise we recommend testing all patients with an abnor-
mal LFT who were born in a country of intermediate
or high prevalence and all patients for whom the ALT
exceeds twice the limit of normal.
The probability of chronic viral hepatitis is low even
when the ALT exceeds this limit and the patient does
not originate from a medium or high-risk country
(1.6%). Nevertheless we advocate testing in these
patients for the following reasons:
1. It is hard to ignore a level this high, and the wide
confidence levels from our data suggest the need for
flexibility [45].
2. The progression for undetected chronic viral
hepatitis is worse for patients with ALT greater than
twice the upper limit of normal, and this level has
been used as a threshold for treatment in guidelines.
3. If chronic viral hepatitis is not present at this level
a more in-depth search for other causes of hepato-
cellular damage is indicated.
We draw the line on further viral testing after this
algorithm has been followed, unless of course further
clinical indicators emerge. The likelihood of a case of
viral hepatitis being present following the exclusions in
this algorithm is approximately 0.1% in our study. This
is considerably below the UK population prevalence.
Conclusions
This analysis indicates that the strategy of repeating
LFTs in asymptomatic patients, advocated by current
guidelines, is less sensitive and far more expensive than
viral testing those patients born in countries where viral
hepatitis is prevalent. Despite few cases of viral hepatitis
the data on costs of the various strategies is strong and
the results of prevalence rates within the cohort are
consistent with other literature. The finding that a nota-
bly raised ALT level was also effective at identifying
infected patients inspired the construction of a “fast and
frugal” heuristic that might aid GPs who are faced with
abnormal LFTs in asymptomatic patients, with regards
to viral hepatitis. Our proposal addresses the diagnostic
problem by identifying a clear high-risk population ori-
ginating in prevalent countries. The residual population
who are not immigrants from such countries are at low
risk. However, this should not override clinical judge-
ment. Its overall cost in other settings will depend on
the relative proportions of patients in these risk-strata,
but our results suggest that the cost of automatic testing
of high-risk individuals will be repaid in terms of addi-
tional cases detected.
Clearly the situation might change as vaccination
catches on in developing countries and needle hygiene
improves. The key points to emerge are that:
1) it is more efficient to determine country of origin
with a view to viral testing, than to simply repeat the
LFT;
2) it is more cost-effective to test the whole LFT posi-
tive population for viral hepatitis, than to repeat the
LFT with a view to viral testing if it remains positive.
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